Janney Montgomery Scott LLC Acquires 452 Shares of Solventum Corporation $SOLV

Janney Montgomery Scott LLC boosted its holdings in shares of Solventum Corporation (NYSE:SOLV) by 1.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 37,696 shares of the company’s stock after acquiring an additional 452 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Solventum were worth $2,859,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in SOLV. Sumitomo Mitsui DS Asset Management Company Ltd lifted its position in shares of Solventum by 0.7% in the 2nd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 19,778 shares of the company’s stock worth $1,500,000 after purchasing an additional 140 shares during the period. Tradition Wealth Management LLC lifted its position in shares of Solventum by 1.6% in the 1st quarter. Tradition Wealth Management LLC now owns 8,830 shares of the company’s stock worth $671,000 after purchasing an additional 143 shares during the period. Perigon Wealth Management LLC lifted its position in shares of Solventum by 3.8% in the 1st quarter. Perigon Wealth Management LLC now owns 4,352 shares of the company’s stock worth $331,000 after purchasing an additional 159 shares during the period. SouthState Corp lifted its position in shares of Solventum by 31.9% in the 1st quarter. SouthState Corp now owns 699 shares of the company’s stock worth $53,000 after purchasing an additional 169 shares during the period. Finally, Brown Lisle Cummings Inc. lifted its position in shares of Solventum by 22.0% in the 1st quarter. Brown Lisle Cummings Inc. now owns 1,038 shares of the company’s stock worth $79,000 after purchasing an additional 187 shares during the period.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. UBS Group started coverage on shares of Solventum in a research report on Wednesday, October 1st. They issued a “neutral” rating and a $77.00 price target on the stock. Wells Fargo & Company boosted their target price on shares of Solventum from $79.00 to $82.00 and gave the company an “equal weight” rating in a research report on Monday, September 15th. Jefferies Financial Group began coverage on shares of Solventum in a research report on Thursday, September 11th. They set a “hold” rating and a $80.00 target price on the stock. Argus upgraded shares of Solventum from a “hold” rating to a “buy” rating and set a $90.00 target price on the stock in a research report on Tuesday, July 1st. Finally, Morgan Stanley upgraded shares of Solventum from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $80.00 to $103.00 in a research report on Tuesday, July 15th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Solventum has an average rating of “Hold” and an average price target of $84.89.

Solventum Stock Performance

SOLV opened at $71.73 on Friday. The company has a current ratio of 1.22, a quick ratio of 0.86 and a debt-to-equity ratio of 2.14. The company’s fifty day moving average price is $72.77 and its two-hundred day moving average price is $72.14. Solventum Corporation has a 1-year low of $60.70 and a 1-year high of $85.92. The company has a market cap of $12.44 billion, a price-to-earnings ratio of 33.21, a PEG ratio of 2.95 and a beta of 0.50.

Solventum (NYSE:SOLV) last announced its earnings results on Thursday, August 7th. The company reported $1.69 EPS for the quarter, beating the consensus estimate of $1.45 by $0.24. The company had revenue of $2.16 billion during the quarter, compared to the consensus estimate of $2.12 billion. Solventum had a net margin of 4.52% and a return on equity of 29.93%. The firm’s revenue for the quarter was up 3.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.56 earnings per share. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. On average, analysts expect that Solventum Corporation will post 6.58 EPS for the current fiscal year.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.